EVER Pharma   Report issue

For profit Phase 4
Founded: Vienna Austria (1934)
Status: Left NME R&D (2016)

Organization Overview

First Clinical Trial
2006
NCT00868283
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Alternative names

EVER Neuro Pharma

Active Ingredients

Drugs in Phase 4 Trials (2)

cenegermin-bkbj (oxervate) (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebral Infarction (Phase 4)

Ischemia (Phase 4)

Stroke (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 2